Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Antineoplastic Agents

All Drugs and Chemicals

Tegafur

Oxaliplatin

Antimetabolites

Envolimab

Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles

Fruquintinib

Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles

Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles

To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Her-2 Negative Unresectable Locally Advanced Gastric Cancer: a National Multicenter Randomized Controlled Study

Defined as the proportion of patients who have undergone surgical resection after multidisciplinary assessment after completing 4-6 cycles of conversion therapy

Measured as the proportion of participants with a pathological complete response at the time of definitive surgery.

The time from opreation to the time when only 50% of the individuals had no relapse or tumor progression

Defined as the percentage of the participants in the analysis population who had a confirmed patial response and complete reponse according to RECIST 1.1 based on investigator assessment

The proportion of participants with a major pathological response (mPR) at the time of definitive surgery.

Defined as no residue under the microscope after resection

The time from enrollment to the time when only 50% of the individuals alive

Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The number of Participants with adverse events will be recorded at each treatment visit.

The quality of life of patients during treatment is eveluated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3.0)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer	NCT05914610	Gastric Cancer	Envolimab Fruquintinib Oxaliplatin Tegafur	18 Years - 75 Years	Fujian Medical University
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer	NCT05914610	Gastric Cancer	Envolimab Fruquintinib Oxaliplatin Tegafur	18 Years - 75 Years	Fujian Medical University

Spots Global Cancer Trial Database for envolimab

Every month we try and update this database with for envolimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for envolimab

Every month we try and update this database with for envolimab cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for envolimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.